[{"link": "https://www.wsj.com/articles/u-s-industrial-production-rises-for-third-straight-month-11597420400", "title": "U.S. Industrial Production Rises for Third Straight Month", "date": "2020-08-14 11:53", "summary": "The measure of output at factories, mines and utilities rose a seasonally adjusted 3% in July. U.S. industrial production increased in July for the third month in a row, as the economy continues its slow recovery.", "categories": [["Economy", "Economic Data"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/economic-data?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"U.S. Industrial Production Rises for Third Straight Month. The measure of output at factories, mines and utilities rose a seasonally adjusted 3% in July. U.S. industrial production increased in July for the third month in a row, as the economy continues its slow recovery.\"\n\nStock Prediction(s):", "Prediction": "\n- General Electric Company (NYSE: GE) will increase because the economy is slowly recovering, and this will help their industrial production.\n- The Boeing Company (NYSE: BA) will increase because the economy is slowly recovering, and this will help their industrial production.\n- United Technologies Corporation (NYSE: UTX) will increase because the economy is slowly recovering, and this will help their industrial production.\n- 3M Company (NYSE: MMM) will increase because"}, {"link": "https://www.wsj.com/articles/funds-get-put-on-mute-due-to-lack-of-need-11600877169", "title": "Funds Get Put on 'MUTE' Due to 'LACK' of 'NEED'", "date": "2020-09-23 12:06", "summary": "As exchange-traded funds bite the dust, so do some clever ticker symbols.. It is a \"DOG\" eat dog world for exchange-traded funds.", "categories": [["Markets", "Overheard"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/overheard?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Funds Get Put on 'MUTE' Due to 'LACK' of 'NEED'. As exchange-traded funds bite the dust, so do some clever ticker symbols.. It is a \"DOG\" eat dog world for exchange-traded funds.\"\n\nStock Prediction(s):", "Prediction": "\n- The market will go down because investors are pulling out of the market because of the lack of need.\n- The market will go up because some clever ticker symbols are being put on \"mute.\""}, {"link": "https://www.wsj.com/articles/facebook-to-counter-apple-privacy-update-with-its-own-prompt-11612191604", "title": "Facebook to Counter Apple Privacy Update With Its Own Prompt", "date": "2021-02-01 11:17", "summary": "Social-media company plans to show users a screen describing how it uses their data to personalize ads. Facebook Inc. plans to roll out an in-app prompt aimed at educating users about the handling of their data as it battles Apple Inc. over the iPhone maker's new privacy changes that would require users' consent to track their behavior and make targeted ads more difficult.", "categories": [["Tech"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Facebook to Counter Apple Privacy Update With Its Own Prompt. Social-media company plans to show users a screen describing how it uses their data to personalize ads. Facebook Inc. plans to roll out an in-app prompt aimed at educating users about the handling of their data as it battles Apple Inc. over the iPhone maker's new privacy changes that would require users' consent to track their behavior and make targeted ads more difficult.\"\n\nStock Prediction(s):", "Prediction": "\n- Facebook, Inc. (NASDAQ: FB) will increase because they are fighting back against Apple's privacy changes.\n- Apple Inc. (NASDAQ: AAPL) will decrease because they are being forced to get user consent for data tracking, which will make targeted ads more difficult."}, {"link": "https://www.wsj.com/articles/indias-central-bank-surprises-with-a-rate-cut-11549521871", "title": "India's Surprise Rate Cut Calls Into Question RBI Independence", "date": "2019-02-07 11:33", "summary": "The easing brings the Reserve Bank of India's policy in line with demands from some politicians and comes ahead of the elections. MUMBAI-India's central bank cut its key lending rate Thursday, surprising economists at a time when the autonomy and reliability of the central bank and other authorities that help manage growth and jobs data in Asia's third-largest economy are being questioned.", "categories": [["Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"India's Surprise Rate Cut Calls Into Question RBI Independence. The easing brings the Reserve Bank of India's policy in line with demands from some politicians and comes ahead of the elections. MUMBAI-India's central bank cut its key lending rate Thursday, surprising economists at a time when the autonomy and reliability of the central bank and other authorities that help manage growth and jobs data in Asia's third-largest economy are being questioned.\"\n\nStock Prediction(s):", "Prediction": "\n- The Reserve Bank of India (RBI) will decrease because they are following the demands of some politicians.\n- HDFC Bank Ltd. (NYSE: HDB) will increase because they are a reliable and stable bank in India.\n- State Bank of India (NYSE: SBI) will decrease because they are a state-owned bank in India."}, {"link": "https://www.wsj.com/articles/youtube-becomes-latest-tech-giant-to-curb-qanon-11602784617", "title": "YouTube Becomes Latest Tech Giant to Curb QAnon", "date": "2020-10-15 13:56", "summary": "Google-owned video service is taking down conspiracy movement's content that promotes violence. YouTube took action against the conspiracy group QAnon, banning videos that call for violence, following the lead of social-media companies that have cracked down on such content.", "categories": [["Tech"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"YouTube Becomes Latest Tech Giant to Curb QAnon. Google-owned video service is taking down conspiracy movement's content that promotes violence. YouTube took action against the conspiracy group QAnon, banning videos that call for violence, following the lead of social-media companies that have cracked down on such content.\"\n\nStock Prediction(s):", "Prediction": "\n- Alphabet Inc. (NASDAQ: GOOGL) will increase because YouTube is one of their subsidiaries, and they have been cracking down on violent content.\n- Facebook, Inc. (NASDAQ: FB) will increase because they have been cracking down on violent content.\n- Twitter, Inc. (NYSE: TWTR) will increase because they have been cracking down on violent content."}, {"link": "https://www.wsj.com/articles/london-stock-exchanges-future-depends-on-brussels-11582901598", "title": "London Stock Exchange's Future Depends on Brussels", "date": "2020-02-28 09:53", "summary": "Investors may be too relaxed about two European Union decisions that are crucial to the company's growth plans. London Stock Exchange Group's future isn't quite the sure thing investors seem to think.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"London Stock Exchange's Future Depends on Brussels. Investors may be too relaxed about two European Union decisions that are crucial to the company's growth plans. London Stock Exchange Group's future isn't quite the sure thing investors seem to think.\"\n\nStock Prediction(s):", "Prediction": "\n- LSEG plc (LSE: LSE) will decrease because the future of their company depends on Brussels, and Brussels may not make the best decisions for them.\n- Deutsche Boerse AG (OTCMKTS: DBOEY) will increase because they are a direct competitor of LSEG, and LSEG's future is uncertain."}, {"link": "https://www.wsj.com/articles/big-tech-wants-you-to-live-in-a-virtual-world-prepare-for-real-problems-11630056626", "title": "The Real Problems of Living in a Virtual World", "date": "2021-08-30 13:23", "summary": "Facebook and other companies view the 'metaverse' as the next big thing, but user discretion is advised. Heard of the \"metaverse\" lately? It has been hard not to.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"The Real Problems of Living in a Virtual World. Facebook and other companies view the 'metaverse' as the next big thing, but user discretion is advised. Heard of the \"metaverse\" lately? It has been hard not to.\"\n\nStock Prediction(s):", "Prediction": "\n- Facebook, Inc. (NASDAQ: FB) will increase because they are one of the main companies pushing for the development of the metaverse.\n- Amazon.com, Inc. (NASDAQ: AMZN) will increase because they are one of the main companies pushing for the development of the metaverse.\n- Apple, Inc. (NASDAQ: AAPL) will increase because they are one of the main companies pushing for the development of the meta"}, {"link": "https://www.wsj.com/articles/daycare-centers-are-very-low-risk-for-covid-19-transmission-study-says-11602699914", "title": "Day-Care Centers Are Very Low Risk for Covid-19 Transmission, Study Says", "date": "2020-10-14 14:25", "summary": "Paper adds new evidence that young children aren't major vectors in coronavirus transmission. Children in day-care programs present virtually no risk of transmitting Covid-19 to adults, according to a new Yale University study of more than 57,000 U.S. child-care providers.", "categories": [["Business", "Health Care", "Health"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/business/health-industry?mod=breadcrumb", "https://www.wsj.com/news/types/health?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Day-Care Centers Are Very Low Risk for Covid-19 Transmission, Study Says. Paper adds new evidence that young children aren't major vectors in coronavirus transmission. Children in day-care programs present virtually no risk of transmitting Covid-19 to adults, according to a new Yale University study of more than 57,000 U.S. child-care providers.\"\n\nStock Prediction(s):", "Prediction": "\n- None"}, {"link": "https://www.wsj.com/articles/morgan-stanley-profit-rises-11626350000", "title": "Morgan Stanley Profit Rises Amid Wall Street Deal Boom", "date": "2021-07-15 11:17", "summary": "Boost in fees from deal making and advising wealthy clients helps bank's results. Morgan Stanley said Thursday that second-quarter profit rose 10% from a year earlier, thanks to a boost in fees from deal making and advising wealthy clients.", "categories": [["Markets", "Finance"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/finance?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Morgan Stanley Profit Rises Amid Wall Street Deal Boom. Boost in fees from deal making and advising wealthy clients helps bank's results. Morgan Stanley said Thursday that second-quarter profit rose 10% from a year earlier, thanks to a boost in fees from deal making and advising wealthy clients.\"\n\nStock Prediction(s):", "Prediction": "\n- Morgan Stanley (NYSE: MS) will increase because they are doing well in the market and their profits are up.\n- Goldman Sachs (NYSE: GS) will decrease because they are a direct competitor of Morgan Stanley.\n- JP Morgan Chase & Co. (NYSE: JPM) will decrease because they are a direct competitor of Morgan Stanley."}, {"link": "https://www.wsj.com/articles/when-it-makes-sense-to-review-your-will-11581608714", "title": "When It Makes Sense to Review Your Will", "date": "2020-02-13 10:45", "summary": "Estate plans should get a second look amid any significant financial changes in your life or changes in estate-tax law. How often do you recommend we should review or consider revising our estate plans/wills?", "categories": [["Markets", "Journal Reports: Wealth Management"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/journal-reports-wealth-management?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"When It Makes Sense to Review Your Will. Estate plans should get a second look amid any significant financial changes in your life or changes in estate-tax law. How often do you recommend we should review or consider revising our estate plans/wills?\"\n\nStock Prediction(s):", "Prediction": "\n- The estate planning industry will increase because people will want to review their wills in light of the changes in the financial and estate-tax landscape.\n- The death care industry will increase because people will want to update their wills to include provisions for their funeral and burial arrangements."}, {"link": "https://www.wsj.com/articles/saba-can-nominate-slate-to-blackrock-fund-boards-delaware-court-says-11561740816", "title": "Saba Can Nominate Slate to BlackRock Fund Boards, Delaware Court Says", "date": "2019-06-28 12:53", "summary": "Saba, run by Boaz Weinstein, had alleged BlackRock was trying to block outsiders from gaining seats and effecting change at closed-end funds. Saba Capital Management LP, a $1.7 billion hedge fund, will be allowed to nominate outsiders to the boards of two BlackRock Inc. closed-end funds.", "categories": [["Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Saba Can Nominate Slate to BlackRock Fund Boards, Delaware Court Says. Saba, run by Boaz Weinstein, had alleged BlackRock was trying to block outsiders from gaining seats and effecting change at closed-end funds. Saba Capital Management LP, a $1.7 billion hedge fund, will be allowed to nominate outsiders to the boards of two BlackRock Inc. closed-end funds.\"\n\nStock Prediction(s):", "Prediction": "\n- Saba Capital Management LP (NYSE: SABA) will increase because they have won their lawsuit against BlackRock and will now be able to nominate outsiders to the boards of two BlackRock Inc. closed-end funds.\n- BlackRock Inc. (NYSE: BLK) will decrease because they were sued by Saba and lost, meaning that they will now have to let Saba nominate outsiders to the boards of two BlackRock Inc. closed-end funds."}, {"link": "https://www.wsj.com/articles/overdraft-fees-are-getting-the-boot-at-ally-financial-11622631600", "title": "Overdraft Fees Are Getting the Boot at Ally Financial", "date": "2021-06-02 12:05", "summary": "Online bank says it will no longer charge the $25 penalty; Ally received positive feedback when it waived the fee early in the pandemic. Overdraft fees are a thing of the past at Ally Financial Inc.", "categories": [["Markets", "Finance"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/finance?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Overdraft Fees Are Getting the Boot at Ally Financial. Online bank says it will no longer charge the $25 penalty; Ally received positive feedback when it waived the fee early in the pandemic. Overdraft fees are a thing of the past at Ally Financial Inc.\"\n\nStock Prediction(s):", "Prediction": "\n- Ally Financial Inc (NYSE: ALLY) will increase because they are no longer charging overdraft fees.\n- JPMorgan Chase & Co. (NYSE: JPM) will decrease because they are still charging overdraft fees."}, {"link": "https://www.wsj.com/articles/comcasts-profit-falls-on-sky-costs-erosion-of-pay-tv-business-11564052468", "title": "Comcast's Profit Falls on Sky Costs, Erosion of Pay-TV Business", "date": "2019-07-25 11:12", "summary": "Cable giant posts strong growth in internet, mobile segments. Comcast Corp. posted a slightly lower profit as strong growth at its internet and mobile business was offset by costs related to the acquisition of European pay-television provider Sky PLC and the continuing erosion of its pay-TV customer base.", "categories": [["Business", "Earnings"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/types/earnings?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Comcast's Profit Falls on Sky Costs, Erosion of Pay-TV Business. Cable giant posts strong growth in internet, mobile segments. Comcast Corp. posted a slightly lower profit as strong growth at its internet and mobile business was offset by costs related to the acquisition of European pay-television provider Sky PLC and the continuing erosion of its pay-TV customer base.\"\n\nStock Prediction(s):", "Prediction": "\n- Comcast Corporation (NASDAQ: CMCSA) will decrease because their profit fell.\n- Disney (NYSE: DIS) will increase because they are in the process of buying Fox, which will give them a larger market share in the cable industry.\n- AT&T (NYSE: T) will decrease because they are losing customers and they are in the process of being sued by the Department of Justice."}, {"link": "https://www.wsj.com/articles/u-s-producer-prices-slipped-from-record-peak-in-december-11642097965", "title": "Producer-Price Increases Slowed From Record Pace in December", "date": "2022-01-13 14:06", "summary": "Prices that suppliers charged businesses and other customers last month rose 0.2% from November, lowest increase in 13 months. Prices that suppliers are charging businesses and other customers closed out 2021 near the highest level in over a decade, though December showed a slight cooling of producer inflation.", "categories": [["Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Producer-Price Increases Slowed From Record Pace in December. Prices that suppliers charged businesses and other customers last month rose 0.2% from November, lowest increase in 13 months. Prices that suppliers are charging businesses and other customers closed out 2021 near the highest level in over a decade, though December showed a slight cooling of producer inflation.\"\n\nStock Prediction(s):", "Prediction": "\n- The producer-price index will continue to slow down because businesses are not able to keep up with the high prices.\n- The producer-price index will stay the same because businesses are still able to keep up with the high prices."}, {"link": "https://www.wsj.com/articles/movie-industrys-troubles-still-far-from-wrapping-up-11601906091", "title": "Movie Industry's Troubles Still Far From Wrapping Up", "date": "2020-10-05 09:54", "summary": "Production delays, lack of insurance could lengthen recovery for already-battered industry. James Bond won't be saving the movie business this year, and the industry may be facing longer-term problems that even the super spy can't fix.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Movie Industry's Troubles Still Far From Wrapping Up. Production delays, lack of insurance could lengthen recovery for already-battered industry. James Bond won't be saving the movie business this year, and the industry may be facing longer-term problems that even the super spy can't fix.\"\n\nStock Prediction(s):", "Prediction": "\n- The movie industry will continue to have troubles because of production delays and the lack of insurance.\n- AMC Entertainment Holdings, Inc. (NYSE: AMC) will decrease because of the movie industry's troubles.\n- Cinemark Holdings, Inc. (NYSE: CNK) will decrease because of the movie industry's troubles.\n- Regal Entertainment Group (NYSE: RGC) will decrease because of the movie industry's troubles."}, {"link": "https://www.wsj.com/articles/what-amazons-rise-to-no-1-says-about-the-stock-market-11547226248", "title": "What Amazon's Rise to No. 1 Says About the Stock Market", "date": "2019-01-11 12:04", "summary": "The biggest companies are still the most dominant. The biggest companies today make up less of the overall market than those in the past. And the biggest companies can still be toppled.. On Jan. 7, Amazon.com Inc. became the world's largest company by market capitalization. Its rise might make you think today's biggest technology companies are turning into unstoppable juggernauts of growth, or that turnover at the top is only accelerating.", "categories": [["Markets", "The Intelligent Investor"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/the-intelligent-investor?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"What Amazon's Rise to No. 1 Says About the Stock Market. The biggest companies are still the most dominant. The biggest companies today make up less of the overall market than those in the past. And the biggest companies can still be toppled.. On Jan. 7, Amazon.com Inc. became the world's largest company by market capitalization. Its rise might make you think today's biggest technology companies are turning into unstoppable juggernauts of growth, or that turnover at the top is only accelerating.\"\n\nStock Prediction(s):", "Prediction": "\n- Amazon.com, Inc. (NASDAQ: AMZN) will continue to increase in value because they are the largest company in the world.\n- Apple Inc. (NASDAQ: AAPL) will continue to decrease in value because they are not the largest company in the world.\n- Microsoft Corporation (NASDAQ: MSFT) will continue to increase in value because they are the second largest company in the world.\n- Facebook, Inc. ("}, {"link": "https://www.wsj.com/articles/fbi-director-hires-new-top-lawyer-from-old-law-firm-11595011758", "title": "FBI Director Hires New Top Lawyer From Old Law Firm", "date": "2020-07-17 14:49", "summary": "Agency's prior general counsel departed amid GOP criticism for role in Russia probe. FBI Director Christopher Wray has tapped a former law partner to be the bureau's next top lawyer as he tries to steady the agency after a series of controversies.", "categories": [["WSJ News Exclusive", "U.S."]], "category_links": ["https://www.wsj.com/news/us?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"FBI Director Hires New Top Lawyer From Old Law Firm. Agency's prior general counsel departed amid GOP criticism for role in Russia probe. FBI Director Christopher Wray has tapped a former law partner to be the bureau's next top lawyer as he tries to steady the agency after a series of controversies.\"\n\nStock Prediction(s):", "Prediction": "\n- FBI Director Christopher Wray will be more popular because he has hired a new top lawyer from his old law firm.\n- The Republican criticism of the FBI will decrease because the new top lawyer is from their old law firm."}, {"link": "https://www.wsj.com/articles/a-reminder-for-ceos-considering-a-shift-in-focus-shareholders-are-still-king-11567791772", "title": "A Reminder for CEOs: Shareholders Are Still King", "date": "2019-09-06 13:42", "summary": "While 181 CEOs say they are committed to serving 'all stakeholders,' when it comes to assessing their own performance, there is really only one master. ", "categories": [["Business", "On Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/types/on-business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"A Reminder for CEOs: Shareholders Are Still King. While 181 CEOs say they are committed to serving 'all stakeholders,' when it comes to assessing their own performance, there is really only one master. \"\n\nStock Prediction(s):", "Prediction": "\n- The CEOs of public companies will continue to put their shareholders first, and their stock prices will reflect this.\n- The CEOs of private companies will put a greater emphasis on social responsibility, and their stock prices will reflect this."}, {"link": "https://www.wsj.com/articles/bankruptcy-watchdog-takes-aim-at-pg-e-ceos-pay-package-11563479934", "title": "Bankruptcy Watchdog Takes Aim at PG&E CEO's Pay Package", "date": "2019-07-18 15:58", "summary": "The U.S. trustee is objecting to the bankrupt California utility's multimillion-dollar pay package for its new chief executive. A federal bankruptcy watchdog is objecting to California utility PG&E Corp.'s request for approval of a $3 million payment to new Chief Executive William Johnson, according to a court document.", "categories": [["Pro Bankruptcy"]], "category_links": ["https://www.wsj.com/pro/bankruptcy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Bankruptcy Watchdog Takes Aim at PG&E CEO's Pay Package. The U.S. trustee is objecting to the bankrupt California utility's multimillion-dollar pay package for its new chief executive. A federal bankruptcy watchdog is objecting to California utility PG&E Corp.'s request for approval of a $3 million payment to new Chief Executive William Johnson, according to a court document.\"\n\nStock Prediction(s):", "Prediction": "\n- PG&E Corp. (NYSE: PCG) will decrease because their CEO is being paid too much money while the company is in bankruptcy.\n- Edison International (NYSE: EIX) will increase because they are not in bankruptcy, and they are a competitor of PG&E."}, {"link": "https://www.wsj.com/articles/bond-investors-shouldnt-fixate-too-much-on-the-alphabet-11550765293", "title": "Bond Investors Shouldn't Fixate Too Much on the Alphabet", "date": "2019-02-21 11:08", "summary": "Corporate debt graded BBB has become investors' bogeyman, but higher-rated paper isn't always safer. Just like a teapot that never whistles while you are looking at it, perhaps the most maligned bit of the corporate bond market isn't where investors will get burned.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Bond Investors Shouldn't Fixate Too Much on the Alphabet. Corporate debt graded BBB has become investors' bogeyman, but higher-rated paper isn't always safer. Just like a teapot that never whistles while you are looking at it, perhaps the most maligned bit of the corporate bond market isn't where investors will get burned.\"\n\nStock Prediction(s):", "Prediction": "\n- The market will not be significantly affected by this news.\n- The market will not be significantly affected by this news."}, {"link": "https://www.wsj.com/articles/feds-evans-says-trade-headwinds-could-justify-additional-rate-cuts-11565194500", "title": "Fed's Evans Says Trade Headwinds Could Justify Additional Rate Cuts", "date": "2019-08-07 15:22", "summary": "Chicago Fed president says the central bank would need to lower rates by at least another quarter-percentage point to lift inflation back to 2% target. CHICAGO-Federal Reserve officials would need to consider more stimulus aimed at boosting the economy if growing trade tensions lead to a sharper pullback, a senior Fed bank president said Wednesday.", "categories": [["Economy", "U.S. Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/u-s-economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Fed's Evans Says Trade Headwinds Could Justify Additional Rate Cuts. Chicago Fed president says the central bank would need to lower rates by at least another quarter-percentage point to lift inflation back to 2% target. CHICAGO-Federal Reserve officials would need to consider more stimulus aimed at boosting the economy if growing trade tensions lead to a sharper pullback, a senior Fed bank president said Wednesday.\"\n\nStock Prediction(s):", "Prediction": "\n- The Federal Reserve (NYSE: FFR) will decrease because they may need to cut rates again if the trade war continues to escalate.\n- The banking sector (NYSE: XLF) will decrease because the Fed is hinting at more rate cuts, which will have a negative impact on banks.\n- The technology sector (NYSE: XLK) will decrease because the Fed is hinting at more rate cuts, which will have a negative impact on the technology sector"}, {"link": "https://www.wsj.com/articles/opioid-risk-smothers-drug-stocks-11565194670", "title": "Opioid Risk Smothers Drug Stocks", "date": "2019-08-07 12:17", "summary": "Fears of massive legal settlements for drug companies such as Teva will keep a lid on stock prices. Even solid corporate earnings can't reverse investor angst over drug companies facing opioid litigation risk.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Opioid Risk Smothers Drug Stocks. Fears of massive legal settlements for drug companies such as Teva will keep a lid on stock prices. Even solid corporate earnings can't reverse investor angst over drug companies facing opioid litigation risk.\"\n\nStock Prediction(s):", "Prediction": "\n- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) will decrease because of the opioid litigation risk.\n- All other drug companies will decrease because of the opioid litigation risk."}, {"link": "https://www.wsj.com/articles/apple-launches-new-airpods-in-wearables-push-11553092528", "title": "Apple Launches New AirPods in Wearables Push", "date": "2019-03-20 10:35", "summary": "Earbuds can access Siri by voice, wirelessly charge. Apple Inc. on Wednesday unveiled a new version of its AirPods wireless earbuds that can activate the virtual assistant Siri by voice, an added feature aimed at extending the momentum of a fast-selling device as iPhone sales cool.", "categories": [["Tech"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Apple Launches New AirPods in Wearables Push. Earbuds can access Siri by voice, wirelessly charge. Apple Inc. on Wednesday unveiled a new version of its AirPods wireless earbuds that can activate the virtual assistant Siri by voice, an added feature aimed at extending the momentum of a fast-selling device as iPhone sales cool.\"\n\nStock Prediction(s):", "Prediction": "\n- Apple Inc. (NASDAQ: AAPL) will increase because they are releasing a new version of their AirPods that have added features.\n- Samsung Electronics Co Ltd (OTC: SSNLF) will decrease because they are a direct competitor of Apple."}, {"link": "https://www.wsj.com/articles/trumps-businesses-face-debt-deadlines-amid-economic-slowdown-11602252225", "title": "Trump's Businesses Face Debt Deadlines Amid Economic Slowdown", "date": "2020-10-09 10:04", "summary": "The Trump Organization could see tougher terms on loans or have to sell assets to raise cash. The Trump Organization faces the prospect of paying more to borrow, getting smaller loans or selling some of its assets to manage more than $400 million of debt coming due on properties hit hard by the economic downturn.", "categories": [["Markets", "Finance"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/finance?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Trump's Businesses Face Debt Deadlines Amid Economic Slowdown. The Trump Organization could see tougher terms on loans or have to sell assets to raise cash. The Trump Organization faces the prospect of paying more to borrow, getting smaller loans or selling some of its assets to manage more than $400 million of debt coming due on properties hit hard by the economic downturn.\"\n\nStock Prediction(s):", "Prediction": "\n- Trump's businesses will have to sell assets to pay off their debts, which will cause their stock prices to decrease.\n- Other businesses that are not related to Trump will have an increase in stock prices because the economy is slowing down."}, {"link": "https://www.wsj.com/articles/did-you-mean-to-be-green-or-to-buy-that-kuwait-fund-11599228509", "title": "Did You Mean to Be Green or to Buy That Kuwait Fund?", "date": "2020-09-04 10:08", "summary": "A new ETF for investing in the petrostate snagged the ticker of a defunct green energy fund. Stock-market listings might look like alphabet soup, but companies, and especially exchange-traded funds, put a good deal of thought into what letters a buyer types into their brokerage's screen when purchasing it. Ideally, it should be memorable and descriptive.", "categories": [["Markets", "Overheard"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/overheard?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Did You Mean to Be Green or to Buy That Kuwait Fund?. A new ETF for investing in the petrostate snagged the ticker of a defunct green energy fund. Stock-market listings might look like alphabet soup, but companies, and especially exchange-traded funds, put a good deal of thought into what letters a buyer types into their brokerage's screen when purchasing it. Ideally, it should be memorable and descriptive.\"\n\nStock Prediction(s):", "Prediction": "\n- The Kuwait Fund (NYSE: KW) will increase because there is now more investor interest in the fund.\n- The Green Energy ETF (NYSE: GEX) will decrease because it is no longer being actively traded."}, {"link": "https://www.wsj.com/articles/shell-can-keep-doing-well-by-doing-good-11572538306", "title": "Shell Can Keep Doing Well by Doing Good", "date": "2019-10-31 12:11", "summary": "Energy giant's positioning as a lower-carbon player has helped it beat peers. Thursday's share drop looks like a buying opportunity.. Royal Dutch Shell reported third-quarter results that beat expectations on earnings and cash flow despite low oil and gas prices but warned that it may take longer to complete its $25 billion share-buyback program.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Shell Can Keep Doing Well by Doing Good. Energy giant's positioning as a lower-carbon player has helped it beat peers. Thursday's share drop looks like a buying opportunity.. Royal Dutch Shell reported third-quarter results that beat expectations on earnings and cash flow despite low oil and gas prices but warned that it may take longer to complete its $25 billion share-buyback program.\"\n\nStock Prediction(s):", "Prediction": "\n- Shell (NYSE: RDS.A) will increase because they are a lower-carbon player and they have beaten peers.\n- Exxon Mobil (NYSE: XOM) will decrease because they are not a lower-carbon player and they have not beaten peers."}, {"link": "https://www.wsj.com/articles/anne-hathaway-asks-3-495-million-for-new-york-penthouse-11582133130", "title": "Anne Hathaway Asks $3.495 Million for New York Penthouse", "date": "2020-02-19 12:25", "summary": "The actress and her husband Adam Shulman raised the ceilings and installed herringbone floors after buying the Upper West Side home for $2.55 million in 2016. Actress Anne Hathaway and her husband Adam Shulman are listing their New York City apartment, a full-floor penthouse in a Neo-Georgian style row house on Manhattan's Upper West Side, for $3.495 million.", "categories": [["WSJ News Exclusive", "Private Properties"]], "category_links": ["https://www.wsj.com/news/types/private-properties?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Anne Hathaway Asks $3.495 Million for New York Penthouse. The actress and her husband Adam Shulman raised the ceilings and installed herringbone floors after buying the Upper West Side home for $2.55 million in 2016. Actress Anne Hathaway and her husband Adam Shulman are listing their New York City apartment, a full-floor penthouse in a Neo-Georgian style row house on Manhattan's Upper West Side, for $3.495 million.\"\n\nStock Prediction(s):", "Prediction": "\n- Hathaway's penthouse will increase in price because it is a desirable location and she has put a lot of work into it.\n- Other properties in the same area will also increase in price because of the demand for this type of housing."}, {"link": "https://www.wsj.com/articles/copper-edges-higher-on-trade-hopes-11558706076", "title": "Copper Prices Rise on Trade Hopes", "date": "2019-05-24 15:16", "summary": "Prices are up after falling in four consecutive sessions through Wednesday. Copper prices edged higher Friday, climbing for the second consecutive session as analysts looked ahead to developments on U.S.-China trade policy.", "categories": [["Markets", "Commodities"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/market-data/commodities?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Copper Prices Rise on Trade Hopes. Prices are up after falling in four consecutive sessions through Wednesday. Copper prices edged higher Friday, climbing for the second consecutive session as analysts looked ahead to developments on U.S.-China trade policy.\"\n\nStock Prediction(s):", "Prediction": "\n- Freeport-McMoRan Inc. (NYSE: FCX) will increase because copper prices are rising.\n- Southern Copper Corp. (NYSE: SCCO) will increase because copper prices are rising.\n- BHP Group Ltd. (NYSE: BHP) will increase because copper prices are rising.\n- Rio Tinto plc (NYSE: RIO) will increase because copper prices are rising."}, {"link": "https://www.wsj.com/articles/wayfair-posts-profit-as-online-pandemic-shoppers-spend-on-their-homes-11596639930", "title": "Wayfair Posts Profit as Online Pandemic Shoppers Spend on Their Homes", "date": "2020-08-05 11:05", "summary": "Wayfair boosts active customer base to 26 million, a 46% year-over-year increase. Online furniture seller Wayfair Inc. turned a profit for the first time since going public in 2014, breaking a string of losses, as more house-bound online shoppers bought home goods during the pandemic-a trend so new and volatile that Chief Executive Niraj Shah said it's hard to predict whether it will last.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Wayfair Posts Profit as Online Pandemic Shoppers Spend on Their Homes. Wayfair boosts active customer base to 26 million, a 46% year-over-year increase. Online furniture seller Wayfair Inc. turned a profit for the first time since going public in 2014, breaking a string of losses, as more house-bound online shoppers bought home goods during the pandemic-a trend so new and volatile that Chief Executive Niraj Shah said it's hard to predict whether it will last.\"\n\nStock Prediction(s):", "Prediction": "\n- Wayfair Inc. (NYSE: W) will continue to increase because more people are buying online and they are one of the few companies that are profitable.\n- Amazon.com, Inc. (NASDAQ: AMZN) will continue to increase because more people are buying online and they are one of the few companies that are profitable.\n- IKEA Group (OTCMKTS: IKEAF) will continue to increase because more people are buying"}, {"link": "https://www.wsj.com/articles/walmart-looks-to-hire-cryptocurrency-expert-11629128826", "title": "Walmart Looks to Hire Cryptocurrency Expert", "date": "2021-08-16 11:47", "summary": "Retailer posts headquarters job to develop digital-currency strategy. Walmart Inc. is seeking to hire a cryptocurrency expert, joining a growing number of companies looking to develop strategies for digital currencies such as bitcoin.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Walmart Looks to Hire Cryptocurrency Expert. Retailer posts headquarters job to develop digital-currency strategy. Walmart Inc. is seeking to hire a cryptocurrency expert, joining a growing number of companies looking to develop strategies for digital currencies such as bitcoin.\"\n\nStock Prediction(s):", "Prediction": "\n- Walmart Inc. (NYSE: WMT) will increase because they are looking to hire a cryptocurrency expert, which shows that they are taking digital currencies seriously.\n- J.P. Morgan Chase & Co. (NYSE: JPM) will decrease because they are not looking to hire a cryptocurrency expert, and they are not as forward-thinking as Walmart."}, {"link": "https://www.wsj.com/articles/bitcoin-coinbase-shiba-inu-alibaba-what-to-watch-when-the-stock-market-opens-today-11638790682", "title": "Bitcoin, Coinbase, Shiba Inu, Alibaba: What to Watch in the Stock Market Today", "date": "2021-12-06 09:38", "summary": "An activist investor urged Kohl's to consider a sale; Alibaba is reorganizing its e-commerce teams. Wall Street indexes were mixed in morning trading as investors considered a small study suggesting that the Omicron variant may cause milder disease. Here's what we're watching in Monday's trading:", "categories": [["Markets", "U.S. Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/today-s-markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Bitcoin, Coinbase, Shiba Inu, Alibaba: What to Watch in the Stock Market Today. An activist investor urged Kohl's to consider a sale; Alibaba is reorganizing its e-commerce teams. Wall Street indexes were mixed in morning trading as investors considered a small study suggesting that the Omicron variant may cause milder disease. Here's what we're watching in Monday's trading:\"\n\nStock Prediction(s):", "Prediction": "\n- Kohl's Corporation (NYSE: KSS) will increase because there is speculation that they will be sold, and Alibaba Group Holding Ltd. (NYSE: BABA) will increase because they are reorganizing their e-commerce teams.\n- The Omicron variant may cause milder disease, so some investors may buy stocks in companies that are working on a vaccine (AstraZeneca plc (NYSE: AZN), Johnson & Johnson (NYSE: J"}, {"link": "https://www.wsj.com/articles/volvo-hit-by-cyber-theft-of-intellectual-property-11639167971", "title": "Volvo Hit by Cyber Theft of Intellectual Property", "date": "2021-12-10 15:26", "summary": "Swedish car maker says cybersecurity breach could have impact on operations. BERLIN- Volvo Car AB, the Swedish car maker, said Friday that it was investigating a cybersecurity breach targeting systems that store research and development files and warned the hack could have an impact on the company's operations.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Volvo Hit by Cyber Theft of Intellectual Property. Swedish car maker says cybersecurity breach could have impact on operations. BERLIN- Volvo Car AB, the Swedish car maker, said Friday that it was investigating a cybersecurity breach targeting systems that store research and development files and warned the hack could have an impact on the company's operations.\"\n\nStock Prediction(s):", "Prediction": "\n- Volvo Car AB (STO: VOLV-B) will decrease because of the cyber theft of intellectual property.\n- Autoliv Inc (NYSE: ALV) will decrease because of the cyber theft of intellectual property.\n- ZF Friedrichshafen AG (ETR: ZFF) will decrease because of the cyber theft of intellectual property."}, {"link": "https://www.wsj.com/articles/repsol-targets-net-zero-emissions-in-strategic-shift-11575360545", "title": "Spanish Energy Giant Repsol Writes Down Oil, Gas Assets", "date": "2019-12-03 11:16", "summary": "Along with warnings of a $5 billion impairment charge, the company said it aims to achieve net-zero emissions by 2050. Spanish energy company Repsol SA said it is cutting the value of its assets by billions of dollars because the global transition to a lower carbon economy is weakening the outlook for oil and gas prices.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Spanish Energy Giant Repsol Writes Down Oil, Gas Assets. Along with warnings of a $5 billion impairment charge, the company said it aims to achieve net-zero emissions by 2050. Spanish energy company Repsol SA said it is cutting the value of its assets by billions of dollars because the global transition to a lower carbon economy is weakening the outlook for oil and gas prices.\"\n\nStock Prediction(s):", "Prediction": "\n- Repsol SA (BME: REP) will decrease because they are writing down their assets and their outlook is weakening.\n- Royal Dutch Shell plc (NYSE: RDS.A) will increase because they are not writing down their assets and their outlook is not weakening.\n- BP plc (NYSE: BP) will increase because they are not writing down their assets and their outlook is not weakening."}, {"link": "https://www.wsj.com/articles/metro-bank-shares-tank-after-pulled-bond-issue-11569344319", "title": "Metro Bank Shares Tank After Pulled Bond Issue", "date": "2019-09-24 12:58", "summary": "Bank had been looking to raise upward of \u00a3200 million but investors only placed \u00a3175 million of orders. Shares in London-listed Metro Bank PLC dropped more than 35% on Tuesday, reaching new lows after the company was forced to pull a bond issue.", "categories": [["Markets", "Stocks", "Europe Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/markets/stocks?mod=breadcrumb", "https://www.wsj.com/news/types/europe-markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Metro Bank Shares Tank After Pulled Bond Issue. Bank had been looking to raise upward of \u00a3200 million but investors only placed \u00a3175 million of orders. Shares in London-listed Metro Bank PLC dropped more than 35% on Tuesday, reaching new lows after the company was forced to pull a bond issue.\"\n\nStock Prediction(s):", "Prediction": "\n- Metro Bank PLC (LON: MTRO) will continue to tank because they were not able to raise the money they were looking for.\n- Barclays PLC (LON: BARC) will increase because they are a competitor of Metro Bank, and they were able to raise the money they were looking for."}, {"link": "https://www.wsj.com/articles/leading-a-digital-overhaul-heres-some-advice-11614889050", "title": "Leading a Digital Overhaul? Here's Some Advice", "date": "2021-03-04 15:17", "summary": "Executive recruiters explain how new tech hires can drive a major revamp. GameStop Corp. , under pressure to digitally transform its operations, announced in early February that it hired former Amazon.com Inc. executive Matt Francis as its first chief technology officer. Mr. Francis was brought in to oversee e-commerce and technology functions.", "categories": [["CIO Journal"]], "category_links": ["https://www.wsj.com/news/types/cio-journal?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Leading a Digital Overhaul? Here's Some Advice. Executive recruiters explain how new tech hires can drive a major revamp. GameStop Corp. , under pressure to digitally transform its operations, announced in early February that it hired former Amazon.com Inc. executive Matt Francis as its first chief technology officer. Mr. Francis was brought in to oversee e-commerce and technology functions.\"\n\nStock Prediction(s):", "Prediction": "\n- GameStop Corp. (NYSE: GME) will increase because they are making a big push into digital transformation, and they have just hired a new CTO.\n- Amazon.com, Inc. (NASDAQ: AMZN) will increase because they are a direct competitor of GameStop, and they are continuing to make big moves in the digital space."}, {"link": "https://www.wsj.com/articles/growth-is-worth-paying-up-for-at-pfizer-11560785531", "title": "Growth Is Worth Paying Up for at Pfizer", "date": "2019-06-17 11:32", "summary": "A $10 billion price tag for cancer development is a reasonable risk for Pfizer to take. A fact of life for health-care companies, as well as patients: Good health care costs money.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Growth Is Worth Paying Up for at Pfizer. A $10 billion price tag for cancer development is a reasonable risk for Pfizer to take. A fact of life for health-care companies, as well as patients: Good health care costs money.\"\n\nStock Prediction(s):", "Prediction": "\n- Pfizer Inc (NYSE: PFE) will increase because they are continuing to grow and invest in their company.\n- Novartis AG (NYSE: NVS) will decrease because they are not investing as much as Pfizer is."}, {"link": "https://www.wsj.com/articles/blue-aprons-beyond-meat-deal-lacks-substance-11563293103", "title": "Blue Apron's Beyond Meat Deal Lacks Substance", "date": "2019-07-16 12:05", "summary": "Partnership sent meal kit's stock flying, but appetite for company's vegan meals likely to be short-lived. Everything Beyond Meat touches turns to gold, it seems.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Blue Apron's Beyond Meat Deal Lacks Substance. Partnership sent meal kit's stock flying, but appetite for company's vegan meals likely to be short-lived. Everything Beyond Meat touches turns to gold, it seems.\"\n\nStock Prediction(s):", "Prediction": "\n- Blue Apron Holdings, Inc. (NYSE: APRN) will decrease because their partnership with Beyond Meat is not as substantial as investors thought it would be.\n- Beyond Meat, Inc. (NASDAQ: BYND) will increase because their partnership with Blue Apron Holdings is very substantial, and investors are likely to have an appetite for their vegan meals."}, {"link": "https://www.wsj.com/articles/is-this-tiny-dishwasher-worth-it-11548779741", "title": "Does the Convenience of a Countertop Dishwasher Outweigh the Hassle?", "date": "2019-01-29 11:35", "summary": "Handwashing dishes is everyone's least favorite chore, but this innovative new kitchen appliance might be as much a nuisance as it is a novelty. FACT: LITERALLY everyone hates doing dishes. A 2018 Council of Contemporary Families report found the disgusting duty to be the least popular of all household chores, affecting even the sex lives of couples who don't equitably share the task. Unfortunately not all households have great big dishwashers to hide grotty plates during the day and run loads at night. In cities like New York and San Francisco, slim, built-in dishwashers have become a coveted feature for anxious apartment hunters.", "categories": [["Tech", "Personal Tech", "Gear & Gadgets"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb", "https://www.wsj.com/news/types/personal-technology-joanna-stern?mod=breadcrumb", "https://www.wsj.com/news/types/gear?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Does the Convenience of a Countertop Dishwasher Outweigh the Hassle?. Handwashing dishes is everyone's least favorite chore, but this innovative new kitchen appliance might be as much a nuisance as it is a novelty. FACT: LITERALLY everyone hates doing dishes. A 2018 Council of Contemporary Families report found the disgusting duty to be the least popular of all household chores, affecting even the sex lives of couples who don't equitably share the task. Unfortunately not all households have great big dishwashers to hide grotty plates during the day and run loads at night. In cities like New York and San Francisco, slim, built-in dishwashers have become a coveted feature for anxious apartment hunters.\"\n\nStock Prediction(s):", "Prediction": "\n- KitchenAid (NYSE: KA) will increase because their countertop dishwasher is a new and innovative appliance that is much more convenient than handwashing dishes.\n- Whirlpool Corporation (NYSE: WHR) will decrease because they are also working on a countertop dishwasher, but their appliance is not as innovative as KitchenAid's."}, {"link": "https://www.wsj.com/articles/blue-apron-delivers-better-margins-as-business-shrinks-11556628024", "title": "Blue Apron Delivers Better Margins as Business Shrinks", "date": "2019-04-30 09:56", "summary": "Meal-kit maker continues to shed customers. Blue Apron Holdings Inc. posted its first quarterly profit by one key metric since going public nearly two years ago but continued to lose customers for its meal kits.", "categories": [["Business", "Earnings"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/types/earnings?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Blue Apron Delivers Better Margins as Business Shrinks. Meal-kit maker continues to shed customers. Blue Apron Holdings Inc. posted its first quarterly profit by one key metric since going public nearly two years ago but continued to lose customers for its meal kits.\"\n\nStock Prediction(s):", "Prediction": "\n- Blue Apron Holdings Inc. (NYSE: APRN) will continue to lose customers because their business is shrinking."}, {"link": "https://www.wsj.com/articles/government-bond-yields-slide-as-investors-grapple-with-muddied-economic-picture-11621606864", "title": "Government Bond Yields Fall as Investors Grapple With Muddied Economic Picture", "date": "2021-05-21 13:42", "summary": "Treasurys and European government bond yields dip after a volatile week of trading. Government bond yields in the U.S. and Europe are ending the week on a downward note with investors seeking safety after a volatile few days in stocks, bonds and cryptocurrencies.", "categories": [["Markets", "Credit Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/credit-markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Government Bond Yields Fall as Investors Grapple With Muddied Economic Picture. Treasurys and European government bond yields dip after a volatile week of trading. Government bond yields in the U.S. and Europe are ending the week on a downward note with investors seeking safety after a volatile few days in stocks, bonds and cryptocurrencies.\"\n\nStock Prediction(s):", "Prediction": "\n- The yield on the 10-year U.S. Treasury note will continue to fall because investors are still uncertain about the economic picture.\n- The yield on the 2-year U.S. Treasury note will continue to fall because investors are still uncertain about the economic picture.\n- The yield on the German 10-year Bund will continue to fall because investors are still uncertain about the economic picture.\n- The yield on the Italian 10-year BTP will"}, {"link": "https://www.wsj.com/articles/apples-october-event-expect-new-macbook-pro-and-airpods-11634566798", "title": "Apple Unveils Redesigned MacBook Pro, New AirPods", "date": "2021-10-18 14:54", "summary": "At 'Unleashed' streamed event, company reveals newest high-end laptops and Apple-designed chips. A pair of MacBook Pro laptops-and a pair of chips-shared center stage at Apple Inc.'s streamed Monday event, which also included the debut of new AirPods.", "categories": [["Tech", "Personal Tech", "Personal Technology: Review"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb", "https://www.wsj.com/news/types/personal-technology-joanna-stern?mod=breadcrumb", "https://www.wsj.com/news/types/personal-technology-wilson-rothman?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Apple Unveils Redesigned MacBook Pro, New AirPods. At 'Unleashed' streamed event, company reveals newest high-end laptops and Apple-designed chips. A pair of MacBook Pro laptops-and a pair of chips-shared center stage at Apple Inc.'s streamed Monday event, which also included the debut of new AirPods.\"\n\nStock Prediction(s):", "Prediction": "\n- Apple Inc. (NASDAQ: AAPL) will increase because they have released a new product that is likely to be successful.\n- Intel Corporation (NASDAQ: INTC) will decrease because they are a direct competitor of Apple.\n- Qualcomm Inc. (NASDAQ: QCOM) will decrease because they are a direct competitor of Apple."}, {"link": "https://www.wsj.com/articles/rupert-murdoch-buys-200-million-montana-ranch-from-the-koch-family-11639065752", "title": "Rupert Murdoch Buys $200 Million Montana Ranch From the Koch Family", "date": "2021-12-09 11:02", "summary": "The media mogul and his wife, Jerry Murdoch, purchased a cattle ranch spanning about 340,000 acres near Yellowstone National Park. Media mogul Rupert Murdoch and his wife, Jerry Murdoch, have purchased a Montana cattle ranch spanning about 340,000 acres from Matador Cattle Co., a subsidiary of Koch Industries. The price was roughly $200 million, making it the largest ranch sale in Montana history, according to people with knowledge of the deal.", "categories": [["WSJ News Exclusive", "Private Properties"]], "category_links": ["https://www.wsj.com/news/types/private-properties?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Rupert Murdoch Buys $200 Million Montana Ranch From the Koch Family. The media mogul and his wife, Jerry Murdoch, purchased a cattle ranch spanning about 340,000 acres near Yellowstone National Park. Media mogul Rupert Murdoch and his wife, Jerry Murdoch, have purchased a Montana cattle ranch spanning about 340,000 acres from Matador Cattle Co., a subsidiary of Koch Industries. The price was roughly $200 million, making it the largest ranch sale in Montana history, according to people with knowledge of the deal.\"\n\nStock Prediction(s):", "Prediction": "\n- Koch Industries, Inc. (NYSE: KHC) will increase because Rupert Murdoch is a big investor in the company and this will bring more attention to it.\n- Sinclair Broadcast Group, Inc. (NASDAQ: SBGI) will increase because Rupert Murdoch is a big investor in the company and this will bring more attention to it."}, {"link": "https://www.wsj.com/articles/sen-ron-wydens-capital-gains-tax-plan-devotes-trillions-to-social-security-11568296801", "title": "Sen. Ron Wyden's Capital-Gains Tax Plan Devotes Trillions to Social Security", "date": "2019-09-12 10:00", "summary": "A leading Democrat prepares for 2021, offering more details on plan to tax annual gains as income. WASHINGTON-Sen. Ron Wyden's proposal to restructure and increase capital-gains taxes would generate at least $1.5 trillion over a decade, dedicated to extending the solvency of Social Security, according to a more detailed plan the senator is releasing Thursday.", "categories": [["Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Sen. Ron Wyden's Capital-Gains Tax Plan Devotes Trillions to Social Security. A leading Democrat prepares for 2021, offering more details on plan to tax annual gains as income. WASHINGTON-Sen. Ron Wyden's proposal to restructure and increase capital-gains taxes would generate at least $1.5 trillion over a decade, dedicated to extending the solvency of Social Security, according to a more detailed plan the senator is releasing Thursday.\"\n\nStock Prediction(s):", "Prediction": "\n- Wyden's proposal will be good for the social security system, and it will help to extend its solvency.\n- The proposal will be bad for the stock market because it will lead to less investment and capital gains.\n- Other stocks that will be affected include: Berkshire Hathaway Inc. (NYSE: BRK.A), Facebook Inc. (NASDAQ: FB), Amazon.com, Inc. (NASDAQ: AMZN)"}, {"link": "https://www.wsj.com/articles/slack-files-eu-antitrust-complaint-against-microsoft-11595423056", "title": "Slack Files EU Antitrust Complaint Against Microsoft", "date": "2020-07-22 11:33", "summary": "Slack alleges that Microsoft forces Office users to install the Teams software. Business-messaging app Slack has filed an antitrust complaint against Microsoft Corp. in the European Union, accusing the software giant of abusing its dominance in allegations that echo the Windows-maker's competition battles more than a decade ago.", "categories": [["Tech"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Slack Files EU Antitrust Complaint Against Microsoft. Slack alleges that Microsoft forces Office users to install the Teams software. Business-messaging app Slack has filed an antitrust complaint against Microsoft Corp. in the European Union, accusing the software giant of abusing its dominance in allegations that echo the Windows-maker's competition battles more than a decade ago.\"\n\nStock Prediction(s):", "Prediction": "\n- Microsoft Corporation (NASDAQ: MSFT) will decrease because they are being sued by Slack for antitrust violations.\n- Amazon.com, Inc. (NASDAQ: AMZN) will increase because they are not being sued by Slack, and they are a direct competitor of Microsoft."}, {"link": "https://www.wsj.com/articles/trade-uncertainty-likely-to-cut-u-s-growth-by-more-than-1-fed-research-says-11567702473", "title": "Trade Uncertainty Likely to Cut U.S. Growth by More Than 1%, Fed Says", "date": "2019-09-05 12:54", "summary": "Economists charted certainty with text analyses of newspaper articles, corporate-earnings calls. Uncertainty over trade policy is likely to reduce U.S. economic output by more than 1% through early 2020, new research from Federal Reserve economists suggests.", "categories": [["Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Trade Uncertainty Likely to Cut U.S. Growth by More Than 1%, Fed Says. Economists charted certainty with text analyses of newspaper articles, corporate-earnings calls. Uncertainty over trade policy is likely to reduce U.S. economic output by more than 1% through early 2020, new research from Federal Reserve economists suggests.\"\n\nStock Prediction(s):", "Prediction": "\n- The uncertainty over trade policy will continue to have a negative impact on the stock prices of companies that rely on exports.\n- The uncertainty over trade policy will continue to have a negative impact on the stock prices of companies that rely on imports.\n- The uncertainty over trade policy will continue to have a negative impact on the stock prices of companies that manufacture goods in the United States."}, {"link": "https://www.wsj.com/articles/mcdonalds-to-back-diverse-restaurant-owners-11638977402", "title": "McDonald's to Back Diverse Restaurant Owners", "date": "2021-12-08 10:30", "summary": "Chain says it will put millions into loans to boost minority representation. McDonald's Corp. said Wednesday it would offer $250 million in low-interest loans to new franchisees over the next five years as a way to help increase diverse ownership of its U.S. restaurants.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"McDonald's to Back Diverse Restaurant Owners. Chain says it will put millions into loans to boost minority representation. McDonald's Corp. said Wednesday it would offer $250 million in low-interest loans to new franchisees over the next five years as a way to help increase diverse ownership of its U.S. restaurants.\"\n\nStock Prediction(s):", "Prediction": "\n- McDonald's Corp. (NYSE: MCD) will increase because they are trying to increase diversity in their franchisees, and this will help their business.\n- Yum! Brands, Inc. (NYSE: YUM) will decrease because they are a direct competitor of McDonald's."}, {"link": "https://www.wsj.com/articles/european-union-aims-for-clarity-in-murky-world-of-sustainable-investing-11619020300", "title": "EU Aims for Clarity in Murky World of Sustainable Investing", "date": "2021-04-21 11:51", "summary": "Large U.S. banks are bracing for more ESG regulation in Europe and America. The European Union put forward a package of measures that took aim at the patchy data available around sustainable investing, seen as one of the fast-growing market's biggest problems.", "categories": [["Markets", "Financial Regulation"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/financial-regulation?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"EU Aims for Clarity in Murky World of Sustainable Investing. Large U.S. banks are bracing for more ESG regulation in Europe and America. The European Union put forward a package of measures that took aim at the patchy data available around sustainable investing, seen as one of the fast-growing market's biggest problems.\"\n\nStock Prediction(s):", "Prediction": "\n- Goldman Sachs Group Inc (NYSE: GS) will increase because they are one of the few banks that have been proactive in sustainable investing.\n- JPMorgan Chase & Co. (NYSE: JPM) will increase because they are one of the few banks that have been proactive in sustainable investing.\n- Bank of America Corp (NYSE: BAC) will increase because they are one of the few banks that have been proactive in sustainable investing.\n- Citigroup Inc (NYSE"}, {"link": "https://www.wsj.com/articles/carlos-ghosn-gaunt-and-gray-haired-methodically-plans-his-defense-11546958114", "title": "After 50 Long Days in Jail, Ghosn Is Sharp as He Prepares His Defense", "date": "2019-01-08 09:35", "summary": "Former Nissan chairman is 'super-calm and rational' with his team, focusing on how to win his case. TOKYO-His cheeks are sunken and his once-robust frame has turned gaunt, but after 50 days in jail, Carlos Ghosn is still the hyperrational, results-oriented engineer who made it to the top of the auto industry. This time, instead of higher profits, the result he seeks is his own freedom and vindication.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"After 50 Long Days in Jail, Ghosn Is Sharp as He Prepares His Defense. Former Nissan chairman is 'super-calm and rational' with his team, focusing on how to win his case. TOKYO-His cheeks are sunken and his once-robust frame has turned gaunt, but after 50 days in jail, Carlos Ghosn is still the hyperrational, results-oriented engineer who made it to the top of the auto industry. This time, instead of higher profits, the result he seeks is his own freedom and vindication.\"\n\nStock Prediction(s):", "Prediction": "\n- Renault SA (EPA: RNO) will increase because Ghosn is still the CEO, and he is focusing on how to win his case.\n- Nissan Motor Co Ltd (TSE: 7201) will increase because Ghosn is still the CEO, and he is focusing on how to win his case.\n- Mitsubishi Motors Corp (TSE: 7211) will increase because Ghosn is still the CEO, and he is focusing"}, {"link": "https://www.wsj.com/articles/feds-evans-sees-coronavirus-casting-a-long-shadow-on-economy-11586368770", "title": "Fed's Evans Sees Coronavirus Casting a Long Shadow on Economy", "date": "2020-04-08 15:18", "summary": "Federal Reserve Bank of Chicago president says consumers, businesses expending resources to stay afloat could impact eventual recovery. Federal Reserve Bank of Chicago President Charles Evans said he's expecting substantial economic pain during the second quarter due to the coronavirus crisis and warned that because companies and households are expending savings and other resources to hold on, that could weigh down a hoped for recovery.", "categories": [["Economy", "U.S. Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/u-s-economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Fed's Evans Sees Coronavirus Casting a Long Shadow on Economy. Federal Reserve Bank of Chicago president says consumers, businesses expending resources to stay afloat could impact eventual recovery. Federal Reserve Bank of Chicago President Charles Evans said he's expecting substantial economic pain during the second quarter due to the coronavirus crisis and warned that because companies and households are expending savings and other resources to hold on, that could weigh down a hoped for recovery.\"\n\nStock Prediction(s):", "Prediction": "\n- The Fed's Evans' comments will have a negative impact on the markets as a whole.\n- Bank of America Corp (NYSE: BAC) will decrease because of the Fed's comments.\n- JPMorgan Chase & Co. (NYSE: JPM) will decrease because of the Fed's comments.\n- Goldman Sachs Group Inc. (NYSE: GS) will decrease because of the Fed's comments.\n- Citigroup Inc. (NYSE: C) will decrease"}, {"link": "https://www.wsj.com/articles/hsbcs-loan-losses-hint-at-tougher-times-for-banks-11588090776", "title": "HSBC's Loan Losses Hint at Tougher Times for Banks", "date": "2020-04-28 12:19", "summary": "Almost a quarter of the lender's $3 billion provision was for one borrower, highlighting the risks of portfolio concentration. HSBC 's Asian focus gives it a slight lead over its European and U.S. peers in understanding the impact of coronavirus shutdowns. Its first-quarter numbers stand as a warning.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"HSBC's Loan Losses Hint at Tougher Times for Banks. Almost a quarter of the lender's $3 billion provision was for one borrower, highlighting the risks of portfolio concentration. HSBC 's Asian focus gives it a slight lead over its European and U.S. peers in understanding the impact of coronavirus shutdowns. Its first-quarter numbers stand as a warning.\"\n\nStock Prediction(s):", "Prediction": "\n- HSBC Holdings plc (NYSE: HSBC) will decrease because of their loan losses.\n- JPMorgan Chase & Co. (NYSE: JPM) will decrease because of their loan losses.\n- Bank of America Corp (NYSE: BAC) will decrease because of their loan losses.\n- Citigroup Inc. (NYSE: C) will decrease because of their loan losses."}, {"link": "https://www.wsj.com/articles/kkr-earnings-rise-as-private-equity-portfolio-climbs-11635850320", "title": "KKR Earnings Rise, as Private-Equity Portfolio Climbs 9%", "date": "2021-11-02 11:52", "summary": "Firm says the part of profit that could be returned to shareholders surged in the third quarter. KKR & Co. reported an increase in third-quarter earnings, and the portion of profit that it could return to shareholders more than doubled.", "categories": [["Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"KKR Earnings Rise, as Private-Equity Portfolio Climbs 9%. Firm says the part of profit that could be returned to shareholders surged in the third quarter. KKR & Co. reported an increase in third-quarter earnings, and the portion of profit that it could return to shareholders more than doubled.\"\n\nStock Prediction(s):", "Prediction": "\n- KKR & Co. LP (NYSE: KKR) will increase because they are reporting an increase in earnings, and the portion of profit that could be returned to shareholders surged.\n- Blackstone Group LP (NYSE: BX) will decrease because they are a direct competitor of KKR."}, {"link": "https://www.wsj.com/articles/snap-says-it-won-t-promote-snapchat-account-of-president-trump-11591207352", "title": "Snap Says It Won't Promote Trump's Snapchat Account", "date": "2020-06-03 15:42", "summary": "Social-media company determines president's public comments could incite violence. Social-media company Snap Inc. said Wednesday that it would no longer promote the Snapchat account of President Trump on its home page after finding that his public remarks could incite racial violence, a spokeswoman said.", "categories": [["Tech"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Snap Says It Won't Promote Trump's Snapchat Account. Social-media company determines president's public comments could incite violence. Social-media company Snap Inc. said Wednesday that it would no longer promote the Snapchat account of President Trump on its home page after finding that his public remarks could incite racial violence, a spokeswoman said.\"\n\nStock Prediction(s):", "Prediction": "\n- Snap Inc. (NYSE: SNAP) will decrease because they are refusing to promote the Trump account, which could cause political backlash.\n- Facebook Inc. (NASDAQ: FB) will increase because they are not refusing to promote the Trump account, and they are a direct competitor of Snap."}, {"link": "https://www.wsj.com/articles/libyan-warlords-oil-foray-draws-u-s-u-n-scrutiny-11591206614", "title": "Libyan Warlord's Oil Foray Draws U.S., U.N. Scrutiny", "date": "2020-06-03 13:50", "summary": "Probes come after Khalifa Haftar pursues international oil deals to help fund his siege of Tripoli. The U.S. and other powers are investigating suspected efforts by Libyan militia leader Khalifa Haftar to raise funds through oil deals, including with Emirati brokers and Venezuela, according to U.S., European and Libyan officials.", "categories": [["WSJ News Exclusive", "World"]], "category_links": ["https://www.wsj.com/news/world?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Libyan Warlord's Oil Foray Draws U.S., U.N. Scrutiny. Probes come after Khalifa Haftar pursues international oil deals to help fund his siege of Tripoli. The U.S. and other powers are investigating suspected efforts by Libyan militia leader Khalifa Haftar to raise funds through oil deals, including with Emirati brokers and Venezuela, according to U.S., European and Libyan officials.\"\n\nStock Prediction(s):", "Prediction": "\n- BP plc (NYSE: BP) will increase because they have a stake in the Libyan oil industry.\n- Royal Dutch Shell plc (NYSE: RDS.A) will increase because they have a stake in the Libyan oil industry.\n- Chevron Corporation (NYSE: CVX) will increase because they have a stake in the Libyan oil industry.\n- Exxon Mobil Corporation (NYSE: XOM) will increase because they have a stake in the Libyan oil"}, {"link": "https://www.wsj.com/articles/amd-will-need-to-keep-upping-its-game-11578422867", "title": "AMD Will Need to Keep Upping Its Game", "date": "2020-01-07 13:47", "summary": "Chipmaker has masterfully capitalized on Intel's fumbles, but the coming year will be tougher. Investors placed a sizable wager on Advanced Micro Devices long before the chipmaker showed up in Las Vegas on Monday.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"AMD Will Need to Keep Upping Its Game. Chipmaker has masterfully capitalized on Intel's fumbles, but the coming year will be tougher. Investors placed a sizable wager on Advanced Micro Devices long before the chipmaker showed up in Las Vegas on Monday.\"\n\nStock Prediction(s):", "Prediction": "\n- AMD (NASDAQ: AMD) will continue to increase because they have been doing well recently and they are a competitor of Intel.\n- Intel (NASDAQ: INTC) will decrease because they have been doing poorly recently and AMD is taking over the market."}, {"link": "https://www.wsj.com/articles/bonnier-corp-to-sell-its-biggest-u-s-magazines-to-venture-equity-group-11601992861", "title": "Bonnier Corp to Sell Its Biggest U.S. Magazines to Venture Equity Group", "date": "2020-10-06 10:01", "summary": "Deal hands Saveur, Popular Science, Field & Stream and others to North Equity. Magazine publisher Bonnier Corp. has agreed to sell seven of its best-known American titles, including Saveur, Popular Science and Field & Stream, to a venture equity group, the company said.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Bonnier Corp to Sell Its Biggest U.S. Magazines to Venture Equity Group. Deal hands Saveur, Popular Science, Field & Stream and others to North Equity. Magazine publisher Bonnier Corp. has agreed to sell seven of its best-known American titles, including Saveur, Popular Science and Field & Stream, to a venture equity group, the company said.\"\n\nStock Prediction(s):", "Prediction": "\n- Bonnier Corp (NYSE: BON) will decrease because they are selling their magazines.\n- North Equity (private) will increase because they are buying the magazines."}, {"link": "https://www.wsj.com/articles/uber-says-discounts-wont-drive-long-term-growth-in-food-delivery-11571771726", "title": "Uber Says Customer Discounts Won't Drive Long-Term Growth", "date": "2019-10-22 15:15", "summary": "Company's strategy isn't dependent on customer incentives, Uber Everything chief says. LAGUNA BEACH, Calif.-Incentives are a big part of the food-delivery business today but won't be over the long term, the head of Uber Everything said Tuesday.", "categories": [["Tech"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Uber Says Customer Discounts Won't Drive Long-Term Growth. Company's strategy isn't dependent on customer incentives, Uber Everything chief says. LAGUNA BEACH, Calif.-Incentives are a big part of the food-delivery business today but won't be over the long term, the head of Uber Everything said Tuesday.\"\n\nStock Prediction(s):", "Prediction": "\n- Uber Technologies Inc (NYSE: UBER) will increase because they are not dependent on customer discounts for long-term growth.\n- Grubhub Inc (NYSE: GRUB) will decrease because they are dependent on customer discounts for long-term growth."}, {"link": "https://www.wsj.com/articles/grubhub-has-some-finicky-investors-11564505375", "title": "Grubhub Has Some Finicky Investors", "date": "2019-07-30 12:49", "summary": "Grubhub continues to grow diners and restaurants in a crowded market, but investors' confidence in the business is slipping. Grubhub ate its meat but still doesn't get any pudding.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Grubhub Has Some Finicky Investors. Grubhub continues to grow diners and restaurants in a crowded market, but investors' confidence in the business is slipping. Grubhub ate its meat but still doesn't get any pudding.\"\n\nStock Prediction(s):", "Prediction": "\n- Grubhub Inc (NYSE: GRUB) will continue to slip because investors are losing confidence in the business.\n- Yelp Inc (NYSE: YELP) will increase because investors are looking for a better alternative to Grubhub."}, {"link": "https://www.wsj.com/articles/feds-bostic-fed-disinclined-to-penalize-banks-for-emergency-lending-choices-11589831566", "title": "Fed's Bostic: Fed Disinclined to Penalize Banks for Emergency Lending Choices", "date": "2020-05-18 15:52", "summary": "The Federal Reserve Bank of Atlanta President said he doesn't plan to heavily second guess decisions banks have taken during the coronavirus crisis. Federal Reserve Bank of Atlanta President Raphael Bostic said Monday he doesn't plan to heavily second guess decisions banks have taken during the coronavirus crisis.", "categories": [["Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Fed's Bostic: Fed Disinclined to Penalize Banks for Emergency Lending Choices. The Federal Reserve Bank of Atlanta President said he doesn't plan to heavily second guess decisions banks have taken during the coronavirus crisis. Federal Reserve Bank of Atlanta President Raphael Bostic said Monday he doesn't plan to heavily second guess decisions banks have taken during the coronavirus crisis.\"\n\nStock Prediction(s):", "Prediction": "\n- The banking sector will increase because the Fed is not going to penalize them for their emergency lending choices.\n- JPMorgan Chase & Co. (NYSE: JPM) will increase because they are one of the largest banks in the United States, and they have been making a lot of loans to help out businesses and consumers.\n- Bank of America Corp (NYSE: BAC) will increase because they are one of the largest banks in the United States, and they have"}, {"link": "https://www.wsj.com/articles/thanksgiving-dinner-staples-might-be-hard-to-find-thanks-to-supply-chain-issues-11636453800", "title": "Thanksgiving Dinner Staples Are Low in Stock", "date": "2021-11-09 14:52", "summary": "Turkeys, yams and pies are low in supply, though aluminum foil to cover it all will be easier to find than last year. The supply-chain crunch is about to hit another part of American life: Thanksgiving dinner.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Thanksgiving Dinner Staples Are Low in Stock. Turkeys, yams and pies are low in supply, though aluminum foil to cover it all will be easier to find than last year. The supply-chain crunch is about to hit another part of American life: Thanksgiving dinner.\"\n\nStock Prediction(s):", "Prediction": "\n- Aluminum Foil (NYSE: AA) will increase because there is a shortage of it, and it is a necessary component of Thanksgiving dinner.\n- Turkeys (NYSE: TUR) will decrease because there is a shortage of them, and they are a necessary component of Thanksgiving dinner.\n- Yams (NYSE: YAM) will decrease because there is a shortage of them, and they are a necessary component of Thanksgiving dinner.\n- Pies (NYSE"}, {"link": "https://www.wsj.com/articles/hoping-that-cars-will-last-as-long-as-the-loan-11585932161", "title": "Hoping That Cars Will Last as Long as the Loan", "date": "2020-04-03 12:42", "summary": "American auto-loan payment terms have never been so generous. I will gladly pay you Tuesday. Tuesday, April 6, 2027, that is.", "categories": [["Markets", "Overheard"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/overheard?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Hoping That Cars Will Last as Long as the Loan. American auto-loan payment terms have never been so generous. I will gladly pay you Tuesday. Tuesday, April 6, 2027, that is.\"\n\nStock Prediction(s):", "Prediction": "\n- Ford Motor Company (NYSE: F) will increase because they are one of the few companies that are still offering generous car loan terms.\n- General Motors Company (NYSE: GM) will decrease because they are one of the few companies that are no longer offering generous car loan terms."}, {"link": "https://www.wsj.com/articles/sec-chairman-warns-on-practices-that-risk-teachers-retirement-savings-11573829349", "title": "SEC Chairman Warns on Practices That Risk Teachers' Savings", "date": "2019-11-15 09:49", "summary": "Agency launched enforcement initiative after talking to investors at town halls. PHILADELPHIA-A sweeping federal enforcement initiative aimed at sales practices related to retirement savings for teachers began after town halls across the country where the nation's top securities regulator heard things that worried him.", "categories": [["Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"SEC Chairman Warns on Practices That Risk Teachers' Savings. Agency launched enforcement initiative after talking to investors at town halls. PHILADELPHIA-A sweeping federal enforcement initiative aimed at sales practices related to retirement savings for teachers began after town halls across the country where the nation's top securities regulator heard things that worried him.\"\n\nStock Prediction(s):", "Prediction": "\n- Franklin Resources, Inc. (NYSE: BEN) will decrease because their products are being targeted by the SEC.\n- T. Rowe Price Group, Inc. (NASDAQ: TROW) will decrease because their products are being targeted by the SEC.\n- BlackRock, Inc. (NYSE: BLK) will decrease because their products are being targeted by the SEC.\n- Vanguard Group, Inc. (NYSE: VGR) will decrease because their products"}, {"link": "https://www.wsj.com/articles/njoy-a-once-bankrupt-e-cigarette-maker-now-seeks-5-billion-valuation-11556736164", "title": "NJOY, a Once Bankrupt E-Cigarette Maker, Now Seeks $5 Billion Valuation", "date": "2019-05-01 14:56", "summary": "Company rolls out new device and seeks out big tobacco companies looking to take a run at Juul. E-cigarette maker NJOY Holdings Inc. is pursuing a funding round that would value the company at as much as $5 billion, and it is trying to interest big tobacco companies looking to take a run at market leader Juul Labs, according to people familiar with the matter.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"NJOY, a Once Bankrupt E-Cigarette Maker, Now Seeks $5 Billion Valuation. Company rolls out new device and seeks out big tobacco companies looking to take a run at Juul. E-cigarette maker NJOY Holdings Inc. is pursuing a funding round that would value the company at as much as $5 billion, and it is trying to interest big tobacco companies looking to take a run at market leader Juul Labs, according to people familiar with the matter.\"\n\nStock Prediction(s):", "Prediction": "\n- NJOY Holdings Inc. (NYSE: NJOY) will increase because they are a direct competitor of Juul Labs, and they are looking for a $5 billion valuation.\n- Juul Labs (NYSE: JUUL) will decrease because they are a direct competitor of NJOY, and NJOY is looking for a $5 billion valuation."}, {"link": "https://www.wsj.com/articles/mall-operators-simon-and-taubman-pair-up-11581340570", "title": "Mall Operators Simon and Taubman Pair Up", "date": "2020-02-10 15:44", "summary": "Simon to own 80% of the Taubman operating entity when transaction is completed. Simon Property Group Inc. is buying rival mall owner Taubman Centers Inc., a $3.6 billion transaction that demonstrates how the largest U.S. mall owner is pushing ahead with expansion despite headwinds in the industry.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Mall Operators Simon and Taubman Pair Up. Simon to own 80% of the Taubman operating entity when transaction is completed. Simon Property Group Inc. is buying rival mall owner Taubman Centers Inc., a $3.6 billion transaction that demonstrates how the largest U.S. mall owner is pushing ahead with expansion despite headwinds in the industry.\"\n\nStock Prediction(s):", "Prediction": "\n- Simon Property Group Inc. (NYSE: SPG) will increase because they are expanding their business, and this will give them a larger market share.\n- Taubman Centers Inc. (NYSE: TCO) will decrease because they are being bought out by Simon Property Group, and they will no longer be an independent company."}, {"link": "https://www.wsj.com/articles/a-36-000-acre-property-in-new-yorks-adirondacks-asks-180-million-11596032719", "title": "A 36,000-Acre Property in New York's Adirondacks Asks $180 Million", "date": "2020-07-29 10:25", "summary": "The estate was the longtime home of Marylou Whitney, a socialite and horse racing enthusiast who died last year. Whitney Park, a 36,000-acre property in the Adirondacks that has belonged to the prominent Whitney family for more than a century, is hitting the market for $180 million.", "categories": [["WSJ News Exclusive", "Private Properties"]], "category_links": ["https://www.wsj.com/news/types/private-properties?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"A 36,000-Acre Property in New York's Adirondacks Asks $180 Million. The estate was the longtime home of Marylou Whitney, a socialite and horse racing enthusiast who died last year. Whitney Park, a 36,000-acre property in the Adirondacks that has belonged to the prominent Whitney family for more than a century, is hitting the market for $180 million.\"\n\nStock Prediction(s):", "Prediction": "\n- The Whitney family will probably decrease in net worth because of this, as the property is being sold for a large sum of money.\n- Other wealthy landowners in the area will probably increase in net worth because of this, as they will now have more competition for large parcels of land."}, {"link": "https://www.wsj.com/articles/ppg-industries-puts-focus-on-m-a-instead-of-share-buybacks-11612382796", "title": "PPG Industries Puts Focus on M&A Instead of Share Buybacks", "date": "2021-02-03 15:06", "summary": "The paint maker has struck three deals in recent months and is trying to do a fourth one. PPG Industries Inc.'s finance chief is helping vet potential new acquisition targets as the paint maker opts for deals over share buybacks in the year ahead.", "categories": [["CFO Journal"]], "category_links": ["https://www.wsj.com/news/types/cfo-journal?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"PPG Industries Puts Focus on M&A Instead of Share Buybacks. The paint maker has struck three deals in recent months and is trying to do a fourth one. PPG Industries Inc.'s finance chief is helping vet potential new acquisition targets as the paint maker opts for deals over share buybacks in the year ahead.\"\n\nStock Prediction(s):", "Prediction": "\n- PPG Industries Inc. (NYSE: PPG) will increase because they are focusing on M&A instead of share buybacks.\n- Sherwin-Williams Co. (NYSE: SHW) will increase because they are a direct competitor of PPG Industries.\n- Axalta Coating Systems Ltd. (NYSE: AXTA) will increase because they are a direct competitor of PPG Industries."}, {"link": "https://www.wsj.com/articles/colonial-pipeline-hack-shows-ransomware-emergence-as-industrial-scale-threat-11620749675", "title": "Colonial Pipeline Hack Shows Ransomware Emergence as Industrial-Scale Threat", "date": "2021-05-11 12:14", "summary": "Schools, hospitals, companies are targeted by 'cyber weapons of mass destruction'. The cyberattack that knocked offline an essential U.S. gasoline pipeline shows how the dangerous, professional-scale hack-for-ransom threat is spreading rapidly, targeting companies, schools, hospitals and other institutions.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Colonial Pipeline Hack Shows Ransomware Emergence as Industrial-Scale Threat. Schools, hospitals, companies are targeted by 'cyber weapons of mass destruction'. The cyberattack that knocked offline an essential U.S. gasoline pipeline shows how the dangerous, professional-scale hack-for-ransom threat is spreading rapidly, targeting companies, schools, hospitals and other institutions.\"\n\nStock Prediction(s):", "Prediction": "\n- Symantec Corporation (NASDAQ: SYMC) will increase because they offer protection against ransomware and other cyber threats.\n- Palo Alto Networks, Inc. (NYSE: PANW) will increase because they offer protection against ransomware and other cyber threats.\n- FireEye, Inc. (NASDAQ: FEYE) will increase because they offer protection against ransomware and other cyber threats.\n- Check Point Software Technologies Ltd. (NASDAQ: CHKP)"}, {"link": "https://www.wsj.com/articles/retailers-get-another-blow-hand-me-downs-11570030820", "title": "Retailers Get Another Blow: Hand-Me-Downs", "date": "2019-10-02 11:40", "summary": "A new Accenture study shows people will happily give and receive vintage clothing this holiday season. Take your grandpa's style and give it as a gift for Christmas.", "categories": [["Markets", "Overheard"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/overheard?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Retailers Get Another Blow: Hand-Me-Downs. A new Accenture study shows people will happily give and receive vintage clothing this holiday season. Take your grandpa's style and give it as a gift for Christmas.\"\n\nStock Prediction(s):", "Prediction": "\n- Department stores (e.g. Macy's, Sears, J.C. Penney) will increase because people will buy more clothes as gifts.\n- Vintage clothing retailers (e.g. Buffalo Exchange, Plato's Closet) will increase because more people will give and receive vintage clothing."}, {"link": "https://www.wsj.com/articles/united-arab-emirates-threatens-to-pull-out-of-23-billion-f-35-drone-deal-with-u-s-11639491997", "title": "U.A.E. Threatens to Pull Out of $23 Billion F-35, Drone Deal With U.S.", "date": "2021-12-14 13:10", "summary": "Gulf partner complained about security requirements aimed at guarding against Chinese espionage, officials say. WASHINGTON-The United Arab Emirates is threatening to pull out of a multibillion-dollar deal to buy American-made F-35 aircraft, Reaper drones and other advanced munitions, U.S. officials said, in what would be a significant shake-up between two longtime partners increasingly at odds over China's role in the Gulf.", "categories": [["WSJ News Exclusive", "World"]], "category_links": ["https://www.wsj.com/news/world?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"U.A.E. Threatens to Pull Out of $23 Billion F-35, Drone Deal With U.S.. Gulf partner complained about security requirements aimed at guarding against Chinese espionage, officials say. WASHINGTON-The United Arab Emirates is threatening to pull out of a multibillion-dollar deal to buy American-made F-35 aircraft, Reaper drones and other advanced munitions, U.S. officials said, in what would be a significant shake-up between two longtime partners increasingly at odds over China's role in the Gulf.\"\n\nStock Prediction(s):", "Prediction": "\n- Lockheed Martin Corporation (NYSE: LMT) will decrease because the United Arab Emirates is threatening to pull out of their multibillion-dollar deal.\n- Boeing (NYSE: BA) will decrease because the United Arab Emirates is threatening to pull out of their multibillion-dollar deal.\n- Northrop Grumman Corporation (NYSE: NOC) will decrease because the United Arab Emirates is threatening to pull out of their multibillion-dollar deal."}, {"link": "https://www.wsj.com/articles/new-alnylam-pharmaceuticals-cfo-faces-competition-challenge-with-pfizer-11562872378", "title": "New Alnylam Pharmaceuticals CFO Faces Competition Challenge With Pfizer", "date": "2019-07-11 15:12", "summary": "The biopharmaceuticals company on Thursday named a former Shire-executive to become its next finance chief. Alnylam Pharmaceuticals Inc. named a new finance chief, a move that comes as the biopharmaceutical company faces new competition from drug giant Pfizer Inc.", "categories": [["CFO Journal"]], "category_links": ["https://www.wsj.com/news/types/cfo-journal?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"New Alnylam Pharmaceuticals CFO Faces Competition Challenge With Pfizer. The biopharmaceuticals company on Thursday named a former Shire-executive to become its next finance chief. Alnylam Pharmaceuticals Inc. named a new finance chief, a move that comes as the biopharmaceutical company faces new competition from drug giant Pfizer Inc.\"\n\nStock Prediction(s):", "Prediction": "\n- Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY) will decrease because they are facing competition from Pfizer.\n- Pfizer Inc. (NYSE: PFE) will increase because they are a direct competitor of Alnylam Pharmaceuticals."}, {"link": "https://www.wsj.com/articles/stocks-to-watch-bed-bath-beyond-sherwin-williams-pricesmart-simulations-plus-aar-11562843265", "title": "Stocks to Watch: Delta, Cigna, Fastenal, Bed Bath & Beyond and More", "date": "2019-07-11 09:50", "summary": "Resume Subscription. Here are some of the companies with shares expected to trade actively in Thursday's session. Stock movements noted by ticker reflect movements during regular trading hours; premarket trading is specified separately.", "categories": [["Markets", "MoneyBeat"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/moneybeat?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Stocks to Watch: Delta, Cigna, Fastenal, Bed Bath & Beyond and More. Resume Subscription. Here are some of the companies with shares expected to trade actively in Thursday's session. Stock movements noted by ticker reflect movements during regular trading hours; premarket trading is specified separately.\"\n\nStock Prediction(s):", "Prediction": "\n- Delta Air Lines, Inc. (NYSE: DAL) will increase because they are expecting a surge in travel due to the vaccine being available.\n- Cigna Corporation (NYSE: CI) will increase because they are expecting a surge in travel due to the vaccine being available.\n- Fastenal Company (NASDAQ: FAST) will increase because they are expecting a surge in demand for their products due to the vaccine being available.\n- Bed Bath"}, {"link": "https://www.wsj.com/articles/u-s-recorded-music-revenue-rises-amid-streaming-subscription-surge-11551380613", "title": "U.S. Recorded-Music Revenue Rises Amid Streaming Subscription Surge", "date": "2019-02-28 14:03", "summary": "Domestic retail revenue grew 12% in 2018 to $9.8 billion as subscriptions to services like Spotify topped 50 million. Revenue from music-streaming platforms now accounts for three-quarters of the music industry's top line, as subscriptions to services including Spotify Technology SA, Apple Inc., Amazon.com Inc. and others in the U.S. grew 42% in 2018 to top 50 million for the first time.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"U.S. Recorded-Music Revenue Rises Amid Streaming Subscription Surge. Domestic retail revenue grew 12% in 2018 to $9.8 billion as subscriptions to services like Spotify topped 50 million. Revenue from music-streaming platforms now accounts for three-quarters of the music industry's top line, as subscriptions to services including Spotify Technology SA, Apple Inc., Amazon.com Inc. and others in the U.S. grew 42% in 2018 to top 50 million for the first time.\"\n\nStock Prediction(s):", "Prediction": "\n- Spotify Technology SA (NYSE: SPOT) will increase because their service is becoming more popular, and more people are subscribing.\n- Apple Inc. (NASDAQ: AAPL) will increase because their service is becoming more popular, and more people are subscribing.\n- Amazon.com Inc. (NASDAQ: AMZN) will increase because their service is becoming more popular, and more people are subscribing.\n- Pandora Media Inc (NYSE: P)"}, {"link": "https://www.wsj.com/articles/toast-test-are-high-tech-toasters-worth-the-price-11581449564", "title": "Toast Test: Are High-Tech Toasters Worth the Price?", "date": "2020-02-11 14:32", "summary": "Do premium toasters-at premium prices-really yield a superior slice? We pitted six smart devices against a classic two-slice machine. THE CA-CHUNK of a triumphant toaster is one of the great All-American sounds. First sold in the 1890s, toasters predate even the advent of sliced bread, itself a response to a turn-of-the-century toasting craze. Most toasters do an adequate job, but since startup culture can't leave even the simplest devices alone, a new breed has popped up to disrupt the searing status quo.", "categories": [["Tech", "Personal Tech", "Gear & Gadgets"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb", "https://www.wsj.com/news/types/personal-technology-joanna-stern?mod=breadcrumb", "https://www.wsj.com/news/types/gear?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Toast Test: Are High-Tech Toasters Worth the Price?. Do premium toasters-at premium prices-really yield a superior slice? We pitted six smart devices against a classic two-slice machine. THE CA-CHUNK of a triumphant toaster is one of the great All-American sounds. First sold in the 1890s, toasters predate even the advent of sliced bread, itself a response to a turn-of-the-century toasting craze. Most toasters do an adequate job, but since startup culture can't leave even the simplest devices alone, a new breed has popped up to disrupt the searing status quo.\"\n\nStock Prediction(s):", "Prediction": "\n- KitchenAid (NYSE: KA) will increase because their toasters are high-tech and worth the price.\n- Breville (OTC: BRVLF) will increase because their toasters are high-tech and worth the price.\n- Cuisinart (NYSE: CCO) will increase because their toasters are high-tech and worth the price.\n- Black & Decker (NYSE: BDK) will decrease because their toasters are"}, {"link": "https://www.wsj.com/articles/u-s-consumer-sentiment-rose-in-recent-weeks-11607703437", "title": "Consumer Sentiment Rose in Recent Weeks", "date": "2020-12-11 11:17", "summary": "Americans' outlook brightened as people expect better economic conditions beyond the pandemic. U.S. consumers grew more confident in the economy in late November and early December, with many expecting the economic conditions to improve when the country begins to exit from the coronavirus pandemic.", "categories": [["Economy", "U.S. Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/u-s-economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Consumer Sentiment Rose in Recent Weeks. Americans' outlook brightened as people expect better economic conditions beyond the pandemic. U.S. consumers grew more confident in the economy in late November and early December, with many expecting the economic conditions to improve when the country begins to exit from the coronavirus pandemic.\"\n\nStock Prediction(s):", "Prediction": "\n- Walmart Inc. (NYSE: WMT) will increase because consumer sentiment is rising, and Walmart is one of the main beneficiaries of this trend.\n- Amazon.com, Inc. (NASDAQ: AMZN) will increase because consumer sentiment is rising, and Amazon is one of the main beneficiaries of this trend.\n- The Coca-Cola Company (NYSE: KO) will increase because consumer sentiment is rising, and The Coca-Cola Company is one of"}, {"link": "https://www.wsj.com/articles/under-armours-never-ending-story-11549992215", "title": "Under Armour's Never-Ending Story", "date": "2019-02-12 12:23", "summary": "The sportswear company's reset, promised since 2017, has yet to take hold. Under Armour 's turnaround plan is looking like the plan that will never end.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Under Armour's Never-Ending Story. The sportswear company's reset, promised since 2017, has yet to take hold. Under Armour 's turnaround plan is looking like the plan that will never end.\"\n\nStock Prediction(s):", "Prediction": "\n- Under Armour, Inc. (NYSE: UA) will continue to decrease because their turnaround plan has not worked."}, {"link": "https://www.wsj.com/articles/auto-borrowing-rises-as-new-mortgage-loans-sag-new-york-fed-says-11549988807", "title": "Auto Borrowing Rises as New Mortgage Loans Sag, New York Fed Says", "date": "2019-02-12 11:26", "summary": "Mortgage originations for 2018 were at lowest level since 2014; auto loans have been steadily moving up since 2010. Americans are borrowing more for cars and less for houses, according to a report released Tuesday by the Federal Reserve Bank of New York.", "categories": [["Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Auto Borrowing Rises as New Mortgage Loans Sag, New York Fed Says. Mortgage originations for 2018 were at lowest level since 2014; auto loans have been steadily moving up since 2010. Americans are borrowing more for cars and less for houses, according to a report released Tuesday by the Federal Reserve Bank of New York.\"\n\nStock Prediction(s):", "Prediction": "\n- Ford Motor Company (NYSE: F) will increase because more people are borrowing for cars instead of houses, and Ford is a major player in the automotive industry.\n- JPMorgan Chase & Co. (NYSE: JPM) will increase because more people are borrowing for cars instead of houses, and JPMorgan is a major player in the automotive industry.\n- General Motors Company (NYSE: GM) will increase because more people are borrowing for cars instead of houses, and General Motors"}, {"link": "https://www.wsj.com/articles/medicare-enrollment-can-be-confusing-and-lead-to-unexpected-costs-11576155600", "title": "Medicare Enrollment Can Be Confusing and Lead to Unexpected Costs", "date": "2019-12-12 11:18", "summary": "More Americans are working past 65 and delaying Social Security, which makes enrolling in Medicare complicated. As more Americans postpone retirement, a growing number are experiencing Medicare enrollment problems that can saddle them with hefty penalties and monthslong coverage gaps.", "categories": [["Markets", "Your Money"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/undefined?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Medicare Enrollment Can Be Confusing and Lead to Unexpected Costs. More Americans are working past 65 and delaying Social Security, which makes enrolling in Medicare complicated. As more Americans postpone retirement, a growing number are experiencing Medicare enrollment problems that can saddle them with hefty penalties and monthslong coverage gaps.\"\n\nStock Prediction(s):", "Prediction": "\n- UnitedHealth Group Inc (NYSE: UNH) will increase because they are the largest health insurance company in the United States.\n- Humana Inc (NYSE: HUM) will increase because they are the second largest health insurance company in the United States.\n- Aetna Inc (NYSE: AET) will increase because they are the third largest health insurance company in the United States.\n- Cigna Corp (NYSE: CI) will increase because they"}, {"link": "https://www.wsj.com/articles/saudis-and-russia-debate-response-to-oil-price-crash-11559831488", "title": "Saudis and Russia Debate Response to Oil-Price Swoon", "date": "2019-06-06 13:18", "summary": "Top oil exporters to meet in Russia ahead of OPEC summit. Saudi Arabia and Russia-the world's top crude exporters-disagree about how to respond to a free fall in oil prices, and their energy ministers are set to meet in Russia in the coming days to build a consensus ahead of a meeting of the Organization of the Petroleum Exporting Countries.", "categories": [["Markets", "Commodities", "Oil Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/market-data/commodities?mod=breadcrumb", "https://www.wsj.com/news/types/oil-markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Saudis and Russia Debate Response to Oil-Price Swoon. Top oil exporters to meet in Russia ahead of OPEC summit. Saudi Arabia and Russia-the world's top crude exporters-disagree about how to respond to a free fall in oil prices, and their energy ministers are set to meet in Russia in the coming days to build a consensus ahead of a meeting of the Organization of the Petroleum Exporting Countries.\"\n\nStock Prediction(s):", "Prediction": "\n- Saudi Aramco (NYSE: ARAMCO) will increase because they are the top crude exporters and they are meeting with Russia to build a consensus.\n- Rosneft Oil (OTCMKTS: RNFTF) will increase because they are the top crude exporters and they are meeting with Russia to build a consensus.\n- Exxon Mobil Corporation (NYSE: XOM) will decrease because they are not the top crude exporters and they are not"}, {"link": "https://www.wsj.com/articles/u-s-to-sell-150-billion-in-debt-11559839298", "title": "U.S. to Sell $150 Billion in Debt", "date": "2019-06-06 12:41", "summary": "Treasury Department will auction next week $74 billion in new debt and $76 billion in previously sold debt. The U.S. will auction $150 billion in securities next week, comprising $74 billion in new debt and $76 billion in previously sold debt. Details (all with minimum denominations of $100):", "categories": [["Markets", "Credit Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/credit-markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"U.S. to Sell $150 Billion in Debt. Treasury Department will auction next week $74 billion in new debt and $76 billion in previously sold debt. The U.S. will auction $150 billion in securities next week, comprising $74 billion in new debt and $76 billion in previously sold debt. Details (all with minimum denominations of $100):\"\n\nStock Prediction(s):", "Prediction": "\n- The U.S. will increase because they are selling a lot of debt.\n- The U.S. Treasury Department will increase because they are auctioning a lot of debt.\n- The Federal Reserve will increase because they are buying a lot of debt."}, {"link": "https://www.wsj.com/articles/ibm-revenue-trends-in-reverse-11548153000", "title": "IBM Revenue Trends in Reverse", "date": "2019-01-22 12:23", "summary": "Red Hat, move toward cloud computing to be scrutinized in earnings report. International Business Machines Corp. is scheduled to report fourth-quarter earnings after the close of trading Tuesday. Here is what to expect:", "categories": [["Tech"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"IBM Revenue Trends in Reverse. Red Hat, move toward cloud computing to be scrutinized in earnings report. International Business Machines Corp. is scheduled to report fourth-quarter earnings after the close of trading Tuesday. Here is what to expect:\"\n\nStock Prediction(s):", "Prediction": "\n- IBM (NYSE: IBM) will decrease because their revenue is in reverse, and they are moving away from cloud computing."}, {"link": "https://www.wsj.com/articles/for-home-builders-a-better-kind-of-recession-11589902608", "title": "For Home Builders, a Better Kind of Recession", "date": "2020-05-19 11:36", "summary": "The housing sector is often stretched heading into a recession, but not this time. The coronavirus pandemic is hammering home builders, but they could emerge from the crisis with less damage than other industries.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"For Home Builders, a Better Kind of Recession. The housing sector is often stretched heading into a recession, but not this time. The coronavirus pandemic is hammering home builders, but they could emerge from the crisis with less damage than other industries.\"\n\nStock Prediction(s):", "Prediction": "\n- Homebuilders such as Lennar Corporation (NYSE: LEN) and KB Home (NYSE: KBH) will increase because they have been less impacted by the pandemic than other industries.\n- REITs such as Simon Property Group, Inc. (NYSE: SPG) and Equity Residential (NYSE: EQR) will decrease because the housing market will be weak going forward."}, {"link": "https://www.wsj.com/articles/google-is-the-only-big-tech-priced-for-trouble-11603214336", "title": "Google Is the Only Big Tech Priced for Trouble", "date": "2020-10-20 13:18", "summary": "Antitrust suit against search giant puts tech investors on notice. Google has turned out to be first in the federal government's firing line. Its big tech peers may pay a bigger price for waiting their turn.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Google Is the Only Big Tech Priced for Trouble. Antitrust suit against search giant puts tech investors on notice. Google has turned out to be first in the federal government's firing line. Its big tech peers may pay a bigger price for waiting their turn.\"\n\nStock Prediction(s):", "Prediction": "\n- Alphabet Inc. (NASDAQ: GOOGL) will decrease because of the antitrust suit, as investors become more wary of the company.\n- Facebook Inc. (NASDAQ: FB) will decrease because of the antitrust suit, as investors become more wary of the company.\n- Amazon.com, Inc. (NASDAQ: AMZN) will decrease because of the antitrust suit, as investors become more wary of the company.\n- Apple Inc."}, {"link": "https://www.wsj.com/articles/earnings-forecasts-are-too-dire-but-still-proceed-with-caution-11594230381", "title": "Earnings Forecasts Are Too Dire, but Still Proceed With Caution", "date": "2020-07-08 13:46", "summary": "Analysts' expectations for S&P 500 earnings seem far too pessimistic since they haven't adjusted for a partial economic rebound, but stocks might have priced that in already. The second quarter probably wasn't as horrible for U.S. companies as estimates suggest. That hardly counts as an all-clear signal as the Covid-19 crisis reasserts itself.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Earnings Forecasts Are Too Dire, but Still Proceed With Caution. Analysts' expectations for S&P 500 earnings seem far too pessimistic since they haven't adjusted for a partial economic rebound, but stocks might have priced that in already. The second quarter probably wasn't as horrible for U.S. companies as estimates suggest. That hardly counts as an all-clear signal as the Covid-19 crisis reasserts itself.\"\n\nStock Prediction(s):", "Prediction": "\n- The market has already priced in a partial economic rebound, so stocks will stay relatively stable.\n- S&P 500 earnings will continue to be dismal, so stocks will continue to decrease."}, {"link": "https://www.wsj.com/articles/food-exporters-resist-chinas-new-coronavirus-restrictions-11593094481", "title": "Food Exporters Resist China's New Coronavirus Restrictions", "date": "2020-06-25 10:14", "summary": "Customs authority requests companies sign documents declaring products aren't contaminated with the virus. China is tightening restrictions on food imports as it seeks to stave off a resurgence of the coronavirus, but its efforts are meeting resistance from government agencies of major food exporters.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Food Exporters Resist China's New Coronavirus Restrictions. Customs authority requests companies sign documents declaring products aren't contaminated with the virus. China is tightening restrictions on food imports as it seeks to stave off a resurgence of the coronavirus, but its efforts are meeting resistance from government agencies of major food exporters.\"\n\nStock Prediction(s):", "Prediction": "\n- Archer Daniels Midland Company (NYSE: ADM) will increase because they are not affected by the new restrictions, and they are a major food exporter.\n- Bunge Ltd. (NYSE: BG) will increase because they are not affected by the new restrictions, and they are a major food exporter.\n- Cargill, Incorporated (NYSE: CARG) will increase because they are not affected by the new restrictions, and they are a"}, {"link": "https://www.wsj.com/articles/gold-ticks-higher-amid-growth-concerns-11553512398", "title": "Gold Rises on Haven Demand, Weaker Dollar", "date": "2019-03-25 15:11", "summary": "Prices have risen about 3.2% for the year; copper inches up.. Gold prices climbed for the third consecutive session Monday, boosted by safe-haven demand with investors around the world fearing a sharp slowdown in global economic growth.", "categories": [["Markets", "Commodities"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/market-data/commodities?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Gold Rises on Haven Demand, Weaker Dollar. Prices have risen about 3.2% for the year; copper inches up.. Gold prices climbed for the third consecutive session Monday, boosted by safe-haven demand with investors around the world fearing a sharp slowdown in global economic growth.\"\n\nStock Prediction(s):", "Prediction": "\n- Goldcorp Inc. (NYSE: GG) will increase because the price of gold is going up.\n- Barrick Gold Corporation (NYSE: ABX) will increase because the price of gold is going up.\n- Newmont Mining Corporation (NYSE: NEM) will increase because the price of gold is going up.\n- AngloGold Ashanti Limited (NYSE: AU) will increase because the price of gold is going up."}]